+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Neurodegenerative Disease Research and Commonalities with Metabolic Diseases, Vol 154. International Review of Neurobiology

  • ID: 4991138
  • Book
  • August 2020
  • Region: Global
  • 322 Pages
  • Elsevier Science and Technology
1 of 2

Metabolic Drivers and Bioenergetic Components of Neurodegenerative Disease summarizes recent developments in intervention trials in neurodegenerative disorders, particularly Alzheimer's and Parkinson's, as well as increasing evidence for the overlap between drivers of metabolic syndrome and neurodegenerative disorders that impact mitochondrial function and bioenergetics, and subsequently cellular function and pathophysiology. Topics covered include Brain Cells Glucose and Ketone Utilization in Brain Ageing and Neurodegenerative Disorders, Role of Senescence in Aging and Aging-Related Disease with Emphasis on and Implications for Neurodegenerative Disorders, Evidence for Pathophysiological Commonalities between Metabolic and Neurodegenerative Disorders, Metabolic Impact on Neuroinflammation and Microglial Modulation in Neurodegenerative Disorders, and much more.

  • Summarizes the impact of the metabolic hypothesis on underlying mechanisms of neurodegenerative disorders
  • Presents the novel treatment strategies based on the metabolic hypothesis for neurodegenerative disorders
Note: Product cover images may vary from those shown
2 of 2
- Status and future directions of clinical trials in Alzheimer's disease

Germán Plascencia-Villa and George Perry

- Tracking the potential involvement of metabolic disease in Alzheimer's disease-Biomarkers and beyond

Jose A. Luchsinger and Henrik Zetterberg

- Brain glucose and ketone utilization in brain aging and neurodegenerative diseases

Dimitrios Kapogiannis and Konstantinos I Avgerinos

- Disturbances in brain energy metabolism in insulin resistance and diabetes and Alzheimer's-Learnings from brain imaging biomarkers

Kerstin Heurling, Edvin Johansson and Antoine Leuzy

- APOE and metabolic dysfunction in Alzheimer's disease

Lance A. Johnson

- Status and future directions of clinical trials in Parkinson's disease

Grazyna Söderbom

- Involvement of GABAergic interneuron dysfunction and neuronal network hyperexcitability in Alzheimer's disease: Amelioration by metabolic switching

Mark P. Mattson

- The mitochondrial hypothesis: Dysfunction, bioenergetic defects, and the metabolic link to Alzheimer's disease

Russell H. Swerdlow

- MAM and C99, key players in the pathogenesis of Alzheimer disease

Marta Pera, Jorge Montesinos, Delfina Larrea, Rishi R. Agrawal, Kevin R. Velasco, Irina G. Stavrovskaya, Taekyung D. Yun and Estela Area-Gomez

- Experimental studies of mitochondrial and lysosomal function in human fibroblasts relevant to Parkinson's disease genetic risk

Ria Thomas, Penelope J. Hallett and Ole Isacson

- Endosomal-lysosomal dysfunction in metabolic disorders and Alzheimer's disease

Michael F. Almeida, Ben A. Bahr and Stephen T. Kinsey

- Metabolic impact on neuroinflammation and microglial modulation in neurodegenerative disorders

Paul Edison

- The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases

Grazyna Söderbom and Bai-Yun Zeng

- Impact of circadian and diurnal rhythms on cellular metabolic function and neurodegenerative disorders

S. Kendall Smith and Erik S. Musiek

- The impact of neurovascular, blood-brain barrier, and glymphatic dysfunction in neurodegenerative and metabolic disorders

Molly Braun and Jeffrey J. Iliff
Note: Product cover images may vary from those shown
3 of 2